The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10493 malaria professionals are enjoying the free benefits of MalariaWorld today

artemisinin-based combination therapy

Surveillance of genetic markers associated with Plasmodium falciparum resistance to artemisinin-based combination therapy in Pakistan, 2018–2019

June 9, 2020 - 16:16 -- Open Access
Author(s): 
Abdul Qader Khan, Leyre Pernaute-Lau, Aamer Ali Khattak, Sanna Luijcx, Berit Aydin-Schmidt, Mubashir Hussain, Taj Ali Khan, Farees Uddin Mufti and Ulrika Morris
Reference: 
Malaria Journal 2020 19:206, 8 June 2020

The spread of artemisinin resistance in the Greater Mekong Subregion of Southeast Asia poses a significant threat for current anti-malarial treatment guidelines globally. The aim of this study was to assess the current prevalence of molecular markers of drug resistance in Plasmodium falciparum in the four provinces with the highest malaria burden in Pakistan, after introducing artemether–lumefantrine as first-line treatment in 2017.

Efficacy and safety of artemisinin-based combination therapy and the implications of Pfkelch13 and Pfcoronin molecular markers in treatment failure in Senegal

June 2, 2020 - 14:08 -- Open Access
Author(s): 
Diallo MA, Yade MS, Ndiaye D, et al.
Reference: 
Sci Rep. 2020 Jun 1; 10(1):8907

In 2006, Senegal adopted artemisinin-based combination therapy (ACT) as first-line treatment in the management of uncomplicated malaria. This study aimed to update the status of antimalarial efficacy more than ten years after their first introduction. This was a randomized, three-arm, open-label study to evaluate the efficacy and safety of artemether-lumefantrine (AL), artesunate-amodiaquine (ASAQ) and dihydroartemisinin-piperaquine (DP) in Senegal.

Molecular surveillance over 14 years confirms reduction of Plasmodium vivax and falciparum transmission after implementation of Artemisinin-based combination therapy in Papua, Indonesia

May 13, 2020 - 13:51 -- Open Access
Author(s): 
Pava Z, Puspitasari AM, Rumaseb A, Handayuni I, Trianty L, Utami RAS, Tirta YK, Burdam F, Kenangalem E, Wirjanata G, Kho S, Trimarsanto H, Anstey NM, Poespoprodjo JR, Noviyanti R, Price RN, Marfurt J, Auburn S
Reference: 
PLoS Negl Trop Dis 14(5): e0008295

Genetic epidemiology can provide important insights into parasite transmission that can inform public health interventions. The current study compared long-term changes in the genetic diversity and structure of co-endemic Plasmodium falciparum and P. vivax populations. The study was conducted in Papua Indonesia, where high-grade chloroquine resistance in P. falciparum and P. vivax led to a universal policy of Artemisinin-based Combination Therapy (ACT) in 2006.

The role of complement immune response on artemisinin-based combination therapy in a population from malaria endemic region of Western Kenya

May 4, 2020 - 15:16 -- Open Access
Author(s): 
Christine N. L. Wanjala, Elke Bergmann-Leitner, Hoseah M. Akala, Geoffrey Odhiambo, Bernhards R. Ogutu, Ben Andagalu, Edwin Kamau and Daniel Ochiel
Reference: 
Malaria Journal 2020 19:168, 29 April 2020

Naturally acquired immunity (NAI), which is characterized by protection against overt clinical disease and high parasitaemia, is acquired with age and transmission intensity. The role of NAI on the efficacy of anti-malarial drugs, including artemisinin-based combinations used as the first-line treatment for uncomplicated Plasmodium falciparum, has not been fully demonstrated. This study investigated the role of NAI in response to artemisinin-based combination therapy (ACT), in symptomatic patients living in western Kenya, a high malaria transmission area.

Evaluation of residual submicroscopic Plasmodium falciparum parasites 3 days after initiation of treatment with artemisinin-based combination therapy

April 23, 2020 - 10:26 -- Open Access
Author(s): 
Richard Mwaiswelo and Bill Ngasala
Reference: 
Malaria Journal 2020 19:162, 21 April 2020

Plasmodium falciparum resistance against artemisinin has not emerged in Africa; however, there are reports of the presence of polymerase chain reaction-determined residual submicroscopic parasitaemia detected on day 3 after artemisinin-based combination therapy (ACT). These residual submicroscopic parasites are thought to represent tolerant/resistant parasites against artemisinin, the fast-acting component of the combination.

First trimester use of artemisinin-based combination therapy and the risk of low birth weight and small for gestational age

April 13, 2020 - 13:45 -- Open Access
Author(s): 
Orvalho Augusto, Andy Stergachis, Esperança Sevene, et al.
Reference: 
Malaria Journal 2020 19:144, 8 April 2020

While there is increasing evidence on the safety of artemisinin-based combination therapy (ACT) for the case management of malaria in early pregnancy, little is known about the association between exposure to ACT during the first trimester and the effect on fetal growth.

Healthcare professionals’ perspective can guide post-marketing surveillance of artemisinin-based combination therapy in Uganda

February 14, 2020 - 16:29 -- Open Access
Author(s): 
Helen Byomire Ndagije, Ronald Kiguba, Niko Speybroeck, et al.
Reference: 
Malaria Journal 2020 19:63, 10 February 2020

Efficient testing to identify poor quality artemisinin-based combination therapy (ACT) is important to optimize efforts to control and eliminate malaria. Healthcare professionals interact with both ACT and malaria patients they treat and hence could observe, first-hand, suspect poor quality artemisinin-based combinations linked to poor malaria treatment outcomes and the factors associated with inappropriate use or treatment failure.

Not Open Access | Imported malaria and artemisinin-based combination therapy failure in travellers returning to Belgium: A retrospective study

November 7, 2019 - 21:48 -- NOT Open Access
Author(s): 
Rovira-Vallbona E, Bottieau E, Guetens P, Verschueren J, Rebolledo J, Nulens E, Van der Hilst J, Clerinx J, Van Esbroeck M, Rosanas-Urgell A
Reference: 
Travel Med Infect Dis. 2019 Oct 30:101505 [Epub ahead of print]

BACKGROUND

Malaria (Plasmodium spp) remains a top cause of travel-associated morbidity among European residents. Here, we describe recent trends of imported malaria to Belgium and characterize the first cases of P.falciparum failure to artemisinin combination therapy (ACT).

METHODS

Country: 
Medical Condition: 

Alternative methods for the Plasmodium falciparum artemisinin ring-stage survival assay with increased simplicity and parasite stage-specificity

February 22, 2016 - 17:19 -- Open Access
Author(s): 
Whitney A. Kite, Viviana A. Melendez-Muniz, Roberto R. Moraes Barros, Thomas E. Wellems and Juliana M. Sá
Reference: 
Malaria Journal 2016 15:94, 17 February 2016

Assessing P. falciparum ART sensitivity in vitro via RSA can be streamlined and accurately evaluated in the laboratory by filtration or sorbitol synchronization methods, thus increasing the accessibility of the assay to research groups.

Usefulness of Plasmodium falciparum-specific rapid diagnostic tests for assessment of parasite clearance and detection of recurrent infections after artemisinin-based combination therapy

October 18, 2013 - 15:57 -- Open Access
Author(s): 
Berit Aydin-Schmidt, Marycelina Mubi, Ulrika Morris, Max Petzold, Billy E Ngasala, Zul Premji, Anders Björkman, Andreas Mårtensson
Reference: 
Malaria Journal 2013, 12:349 (1 October 2013)
MalariaWorld

The results may have implications for the choice of RDT devices in similar transmission settings for improved malaria case management.

Subscribe to RSS - artemisinin-based combination therapy